International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All: 

The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about.

First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in New York City. Here is the registration link should you be in NYC on Thursday and able to attend. Panel discussions will focus on the challenges of developing multi-sectoral national action plans as well as covering progress on support mechanisms for antibiotic discovery. The keynote speakers look wonderful, including opening comments from the WHO’s DG:

  • Session title: One Year On: Progress, Challenges, Opportunities, and New Ways of Working to Tackle Antimicrobial Resistance (AMR)
  • Keynote: Dr. Tedros Adhanom Ghebreyesus; Director-General, World Health Organization; Co-Chair, UN Interagency Coordination Group on AMR
  • Keynote: Professor Dame Sally Davies; Chief Medical Officer, United Kingdom; Co-Convener, UN Interagency Coordination Group
  • Keynote: Ms. Maria Helena Semedo; Deputy Director-General, Food and Agriculture Organization of the United Nations
  • Closing: Honorable Dr. Aaron Motsoaledi; Minister of Health, South Africa

Second, Wellcome Trust is also organizing an AMR Call to Action Conference 12-13 October in Berlin. The event is “… an opportunity for national governments and multilateral institutions to come together with the civil society, private and philanthropic sectors to focus on the most critical gaps in tackling the development and spread of drug-resistant infections, and to commit to concerted and tangible actions.” If you think you might be interested in attending (it is invitation-only but I am told there is still some scope to add attendees), please contact Wellcome Trust by email at amrcalltoaction@wellcome.ac.uk.

It is fabulous to see these conversations at the political level … I know that we don’t yet have all the tools we need to ensure a vibrant antibiotic pipeline, but these conversations are the necessary prelude!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

EPA (part 2, streptomycin!) / $104m ARPA-H AMR project

Dear All (OK, so now it’s 5 newsletters in as many days … exciting times … can’t keep up!), Two follow-up items today. First, yesterday’s newsletter about EPA’s concept note regarding AMR risks of pesticides prompted one of your fellow readers to remind me about this lawsuit filed with the U.S. Court of Appeals, Ninth Circuit: Case

BARDA Medical Countermeasures BAA: Substantial updates

Dear All (and yes, back-to-back newsletters … lots of action this week!): BARDA have today released a new version of their long-running BAA (Broad Agency Announcement, formerly BAA-18-100-SOL-00003) that seeks medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The new BAA is BAA-23-100-SOL-00004 and has been completely reorganized and

Appropriate duration of antimicrobial dosing in food animal care

Dear All,  I’ve watched with interest the way that FDA’s CVM (Center for Veterinary Medicine) has been working steadily with the veterinary community as a whole to reduce antibiotic resistance pressure by improving the way antibiotics are used in animal care. The titles of these prior newsletters give you a feel for some aspects of

Scroll to Top